Innovent Announces First Participant Dosed of IBI128 (tigulixostat, XOI) in Phase 3 Clinical Study
Innovent Biologics, Inc. ($01801) has announced that the first participant has been dosed in a Phase 3 clinical…
6d agoOil Prices Were Mixed in the Morning Asian Session • Gold Prices Slipped Below $5,000 in Thin Trading • Trump Says He Will Be Involved Indirectly in U.S.-Iran Nuclear Talks in Geneva • Global Investors Stay 'Uber-Bullish' as AI Bubble Fears Rise • Aluminum Surges on Trump Tariff Rollback Talk • Oil Prices Were Mixed in the Morning Asian Session • Gold Prices Slipped Below $5,000 in Thin Trading • Trump Says He Will Be Involved Indirectly in U.S.-Iran Nuclear Talks in Geneva • Global Investors Stay 'Uber-Bullish' as AI Bubble Fears Rise • Aluminum Surges on Trump Tariff Rollback Talk
Outlook Therapeutics, Inc. ($OTLK) has commenced a best-efforts public offering of its common stock and accompanying warrants exercisable for shares of its common stock. The…
5d agoInnovent Biologics, Inc. ($01801) has announced that the first participant has been dosed in a Phase 3 clinical…
6d agoAbsci Corporation ($ABSI) granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common…
22d agoGet the 10 most important stories delivered to your inbox every morning. No spam. Unsubscribe anytime.